Impact of thrombophilic gene mutations and graft-versus-host disease on thromboembolic complications after allogeneic hematopoietic stem-cell transplantation

Transplantation
Markus PihuschRudolf Pihusch

Abstract

Hemostatic events in patients undergoing allogeneic hematopoietic stem-cell transplantation (HSCT) increase the morbidity and mortality in this cohort. Little is known about the impact of graft-versus-host disease (GvHD) or of thrombophilic gene mutations/polymorphisms on these complications. Eighty-nine allogeneic stem-cell recipients and their donors were evaluated prospectively for the presence of the factor V G1691A mutation, the prothrombin G20210A mutation, the 5,10-methylenetetrahydrofolate-reductase (MTHFR) C677T mutation, the glycoprotein IIIa PI(a1/a2) polymorphism, the fibrinogen-beta-chain 455G/A polymorphism, the plasminogen activator inhibitor-1 -675 4G/5G polymorphism, and the angiotensin-converting enzyme intron 16 I/D polymorphism. These mutations/polymorphisms and GvHD parameters were correlated to hemostatic and toxic complications after transplantation. The data were compared with those of 128 healthy controls. The PAI-1 4G/4G polymorphism increases the risk for catheter thrombosis after HSCT 5.7-fold (32.2% vs. 71.4%, P<0.05). In patients with hepatic veno-occlusive disease, the frequency of the PAI-1 4G allele is also increased (83.3% vs. 55.1%, NS). Thrombophilic mutations/polymorphisms in donors do not i...Continue Reading

References

Jun 1, 1990·Blood Reviews·T M Cox
Jan 1, 1989·Blood Purification·R A Mactier, K D Nolph
Aug 1, 1988·The Journal of Experimental Medicine·R L MedcalfW D Schleuning
Mar 1, 1986·The Journal of Experimental Medicine·P P Nawroth, D M Stern
Dec 1, 1985·Immunological Reviews·R Storb, E D Thomas
May 1, 1994·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·H M ShulmanG B McDonald
Jun 13, 1998·American Journal of Hematology·M Riordan, P L Weiden
Oct 31, 2001·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·M FischerederW Land

❮ Previous
Next ❯

Citations

Aug 18, 2009·Bone Marrow Transplantation·D PulanicS Z Pavletic
Dec 7, 2011·Pharmacogenetics and Genomics·Kalliopi P SpyridopoulouPantelis G Bagos
Nov 16, 2011·Hämostaseologie·G Stussi, D A Tsakiris
Aug 13, 2015·International Journal of Molecular Sciences·Raffaella FrancaMarco Rabusin
Mar 17, 2009·Best Practice & Research. Clinical Haematology·Dimitrios A Tsakiris, André Tichelli
Aug 17, 2005·Journal of Thrombosis and Haemostasis : JTH·M PihuschUNKNOWN F7BMT-1360 Trial Investigators
Jul 17, 2008·Journal of Thrombosis and Haemostasis : JTH·A GonsalvesD S Allan
Sep 8, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Sharon EladMichael Y Shapira
Jan 24, 2007·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Charles G Mullighan, Peter G Bardy
Aug 22, 2006·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Kim RobienCornelia M Ulrich
Apr 23, 2016·Annals of Hematology·Mohammad Faizan ZahidShahrukh K Hashmi
Nov 9, 2016·Critical Reviews in Oncology/hematology·Ugur SahinTaner Demirer
May 1, 2021·Journal of Personalized Medicine·Nicolas WaespeMarc Ansari

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.